AR and posterior cortical atrophy: Given the key role of the androgen receptor (AR) signaling in PCa growth and progression, several agents targeting this molecular pathway were developed: (i) antiandrogens directly targeting the AR receptor such as bicalutamide, flutamide and nilutamide (first and second generation antiandrogens), and enzalutamide, apalutamide and darolutamide (third generation antiandrogens); (ii) inhibitors of intratumoral androgen synthesis such as finasteride, orteronel and abiraterone [43,62,63,64,65,66,67,68,69].